Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 19,277

Document Document Title
WO/2015/006863A1
Improved processes for extracting polyphenols and/or flavonoids from citrus peels comprising: 1) heating a ground peel to form a pre-treated, ground peel; and 2) extracting the compounds of interest from the pre-treated, ground peel usin...  
WO/2015/009952A1
The invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a ...  
WO/2015/008836A1
 An agent for preventing muscle atrophy and/or promoting muscle synthesis containing, as active ingredients, a basic protein fraction derived from milk and/or a resolvent of a basic protein fraction derived from milk, and whey protein ...  
WO/2015/004485A1
The present invention relates to therapeutic compounds useful for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia). The compounds have the structural formula I shown ...  
WO/2015/004609A3
A method of treating injured tendons in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of placenta- derived adherent stromal cells.  
WO/2015/001995A1
 Provided is a rocuronium preparation that makes it possible to suppress vascular pain. This rocuronium preparation is characterized by containing rocuronium and a buffer and having titratable acidity of 100 mEq or less. The buffer may...  
WO/2014/208354A1
The present invention relates to a pharmaceutical composition for treatment or prophylaxis of inflammatory diseases. A pharmaceutical composition according to the present invention contains, as an active ingredient, a compound that is se...  
WO/2014/210369A3
We provide methods and kits to reverse neuromuscular block caused by a cysteine-inactivated neuromuscular blocking drug, comprising administering to said subject a combination of a cysteine-like agent and an acetylcholinesterase inhibito...  
WO/2014/205045A1
Disclosed herein are methods of improving muscular health, such as enhancing muscle regeneration, maintenance, or repair. In some examples, the method includes administering to the subject an effective amount of an agent capable of incre...  
WO/2014/203518A1
Disclosed are double-stranded antisense nucleic acid complexes that can efficiently alter the processing of RNA in a cell via an antisense effect, and methods for using the same. One method comprises contacting with the cell a double-str...  
WO/2014/204090A1
The present invention discloses a composition comprising a filler and Botulinum toxin for alleviating skin wrinkles or aging or treating neuromuscular diseases. The composition according to the present invention resolves neuromuscular di...  
WO/2014/199935A1
[Problem] To provide a prophylactic or treatment agent for body weight increase or obesity being a side effect of antidepressants, antipsychotic drugs, analgesics, or treatment agents for fibromyalgia. [Solution] A prophylactic or treatm...  
WO/2014/199171A1
The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy.  
WO/2014/199960A1
The present invention provides a novel compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which is useful for prophylaxis or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive imp...  
WO/2014/198164A1
The present invention relates to the field of medicinal chemistry, specifically to a cis-benzylisoquinoline compound (I), a preparation method therefor, a pharmaceutical preparation containing said compound and medical uses thereof. The ...  
WO/2014/199315A1
The present invention relates to novel derivatives of hydrophilic bioactive peptides which have been modified by introducing a lipophilic substituent through esterification of the free carboxylic group(s) of the peptide with an aliphatic...  
WO/2014/200075A1
Provided are 4-alkynyl imidazole derivatives represented by general formula (I) and pharmacologically permissible salts thereof. The derivatives have excellent EP4 receptor antagonist effects and are useful as medicines for treating dise...  
WO/2014/196644A1
The inventors perfected the present invention as a result of a study into IK1 channel activators and a confirmation that a benzothiophene compound exhibits efficacy against visceral pain, inflammatory pain, osteoarthritic pain, neuropath...  
WO/2014/190866A1
Provided is a muscle stem cell in vitro culture method. A muscle stem cell is cultivated in vitro by using a cell culture medium of a cell factor added with a blood cell or a conditioned medium of the blood cell. Also provided are a cult...  
WO/2014/189634A1
The present invention provides, among other things, methods of treating a muscular dystrophy including administering to a subject suffering from or susceptible to a muscular dystrophy an angiotensin (1-7) peptide. The present invention i...  
WO/2014/188198A1
The present invention relates to a method of treating adverse fat accumulation and related conditions with very low doses of tacrolimus or a close structural analogue thereof. In particular this invention relates to treating adverse fat ...  
WO/2014/190250A1
Methods for ameliorating and/or treating the symptoms associated with dystrophic diseases such as Duchenne muscular dystrophy (DMD) in a subject comprising administering to a subject a pharmaceutical composition comprising a nitric oxide...  
WO/2014/188214A1
A topical pharmaceutical composition for use in alleviating or reversing a clinical symptom selected from rigidity, stiffness, loss of mobility, loss of flexibility and swelling in a part or region of the body is described, wherein the c...  
WO/2014/188730A1
Provided is an agent for oral ingestion whereby human motility function can be improved. A motility function-improving agent that comprises lutein and a milk component as active ingredients, said motility function-improving agent being u...  
WO/2014/189475A1
The invention relates to a composition formed for treating the muscle weakness and the loss of muscle mass following the chronic stroke and coma.  
WO/2014/189071A1
 Provided are stem cells for transplantation composed of MSCs capable of overexpression of IL-10 as means for providing: MSCs for transplantation having improved take ratio and cell survivability after transplantation, and having high ...  
WO/2014/189830A1
Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formul...  
WO/2014/183989A1
The present invention relates to collagen hydrolysate as active substance for treating sarcopenia, as active substance against the degenerative loss of muscle mass and for improving muscle power, as active substance for reducing the age-...  
WO/2014/180996A1
The invention relates to the use of 5-azacytidine and pharmaceutically acceptable salts thereof in a method of treating or preventing diseases responsive to inhibition of nonsense-mediated mRNA decay, such as cystic fibrosis, muscular dy...  
WO/2014/181333A3
Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose. Also disclosed is an injectable aqueous pharmaceutical f...  
WO/2014/181813A1
The purpose of the present invention is to provide: a compound having excellent PKC inhibitory activity and is useful as a prophylactic or therapeutic agent for immunologic diseases and inflammatory diseases, etc.; or a salt thereof. The...  
WO/2014/178863A1
The present provides methods for treating spinal muscular atrophy using a self- complementary recombinant adeno-associated virus (rAAV) viral particle comprising a transgene expressing SMN. In one aspect, the viral particles are administ...  
WO/2014/171532A1
[Problem] To provide an anti-human TWEAK antibody having superior activity as compared to conventional anti-human TWEAK antibodies, and a means for preventing or treating various diseases in which human TWEAK is involved in the pathogene...  
WO/2014/169126A1
Agents and methods for increasing dystrophin protein expression in muscle through blocking of specific microRNAs and microRNA binding sites on the dystrophin 3' untranslated region (miR-146a, miRNA-146b, miR-223, miR-320a, miR374a, and m...  
WO/2014/167440A1
The present invention relates to modified release pharmaceutical compositions of cyclobenzaprine or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising unit dosage form o...  
WO/2014/162925A1
The present invention provides a composition for preventing joint aging, containing one or more types of components selected from the group consisting of a component containing rehmannia root, a component containing cornus fruit, a compo...  
WO/2014/165827A1
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demye...  
WO/2014/164969A1
The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.  
WO/2014/157437A1
A propellane derivative represented by general formula (I) (wherein R1 represents a hydrogen atom, a C1-6 alkyl group, a cycloalkylalkyl group (wherein the number of carbon atoms in a cycloalkyl moiety is 3 to 6 and the number of carbon ...  
WO/2014/157380A1
Provided is a means whereby wounds or organ fibrosis can be easily treated within a short period of time. A therapeutic agent for wounds or fibrosis, said therapeutic agent comprising a substance capable of specifically inhibiting the ex...  
WO/2014/157436A1
[Problem] The purpose of the present invention is to provide a formulation technique for improving the percutaneous absorption of diclofenac and/or a pharmaceutically acceptable salt thereof with respect to a pharmaceutical composition f...  
WO/2014/157153A1
A muscle-atrophy-preventing agent containing as active ingredients a milk-derived basic protein fraction and/or a milk-derived basic protein fraction decomposition product. The muscle-atrophy-preventing agent has marked effects for preve...  
WO/2014/160102A1
The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorde...  
WO/2014/153220A3
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.  
WO/2014/148455A1
Provided is a novel terpenoid derivative which exhibits anti-inflammatory action and cytoprotective action by activating Keap1/Nrf2/ARE signal transduction pathways. Terpenoid derivative A is represented by formula (1).  
WO/2014/148646A1
The present invention addresses the problems of: providing a method for producing motor neurons from pluripotent stem cells quickly and in synchronisation, said motor neurons being satisfactorily provided with the properties of inherent ...  
WO/2014/153240A3
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.  
WO/2014/153172A1
Described herein are compounds of Formula (I-a) and (I-b), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT1 activity. Methods of using ...  
WO/2014/148574A1
The purpose of the present invention is to find a substance capable of inhibiting the production of IL-2. The production of IL-2 can be inhibited with a compound represented by general formula (I) (wherein R1 to R4 and A are as defined i...  
WO/2014/144017A3
The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).  

Matches 201 - 250 out of 19,277